This content is from: Premium Cormorant Eyes Three IPOs This Week, Betting on Recent Success More than a half-dozen firms, known for their hedge funds, have previously made investments in the biopharma companies. By Stephen Taub June 21, 2021
This content is from: Premium Casdin, Corvex Are on a SPAC Tear The investment firms filed for their third SPAC — the same week they priced their second one and two weeks after their first blank-check company announced a deal. By Stephen Taub February 25, 2021
This content is from: Premium Corvex and Casdin Founders Plan Their Second SPAC Their first one still has not found a merger partner. By Stephen Taub February 03, 2021
This content is from: Premium Why 2019 Wasn’t All Bad for Unicorns While the recent headlines were negative, 2019 was still a pretty good year for fund raising. By Stephen Taub December 30, 2019
This content is from: Portfolio Venture Capital’s New Favorite Industry Dealmaking is surging around retail health and wellness technology. By Jessica Hamlin June 03, 2021
This content is from: Portfolio Ten-fold Growth and a 740 Percent Stock Gain: Cathie Wood’s Breakout Year by the Numbers ARK Investment Management’s assets grew 11-fold to $34.5 billion over the course of 2020. By Amy Whyte January 20, 2021
